BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
 Annual Meeting - EconoTimes)
EAGAN, Minn., March 27, 2017 -- Biothera Pharmaceuticals Inc. announced today that it will present three scientific posters at the American Association for Cancer Research (AACR) Annual Meeting April 1-5 in Washington, D.C. One poster was selected for the late-breaking session that highlights the newest and most exciting research.
Poster Presentations:
| Session Date & Time: | Monday, April 3, 8:00 AM - 12:00 PM Eastern Time | ||||||||||
| Topic Track: | Immunology | ||||||||||
| Session: | Adaptive Immunity to Cancer | ||||||||||
| Presentation Title: | A novel tumor vaccine platform: direct conjugation of antigens to the β-glucan PAMP Imprime PGG enhances antigen presentation and T cell priming | ||||||||||
| Session Location: | Poster Section 29 | ||||||||||
| Poster Board Number: | 22 | ||||||||||
| Abstract #: | 1703 | ||||||||||
| Session Date & Time: | Tuesday, April 4, 8:00 AM - 12:00 PM Eastern Time | ||
| Topic Track: | Immunology | ||
| Session: | Late-Breaking Research: Immunology | ||
| Presentation Title: | Imprime PGG modulates immunosuppressive myeloid components of the tumor microenvironment and drives enhanced antitumor efficacy in combination with checkpoint inhibitor therapies | ||
| Session Location: | Poster Section 35 | ||
| Poster Board Number: | 22 | ||
| Abstract #: | LB-199 |
| Session Date & Time: | Tuesday, April 4, 8:00 AM - 12:00 PM Eastern Time | ||
| Topic Track: | Immunology | ||
| Session: | Inflammation in the Tumor Microenvironment | ||
| Presentation Title: | Imprime PGG, a novel innate immune therapeutic in phase 2 clinical development, induces mobilization of monocytes and focalized recruitment of innate immune cells to tumor sites | ||
| Session Location: | Poster Section 28 | ||
| Poster Board Number: | 1 | ||
| Abstract #: | 3688 |
About Biothera Pharmaceuticals, Inc.
Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a Phase 2 cancer immunotherapy that enhances the efficacy of anti-cancer immune response in combination with immune checkpoint inhibitor, tumor-targeting and anti-angiogenesis antibodies. Biothera Pharmaceuticals has clinical research agreements with Merck to evaluate Imprime PGG and KEYTRUDA® in Phase 2 studies in advanced melanoma, metastatic triple negative breast cancer, and head and neck squamous cell cancer. This therapeutic combination also is the focus of a Big Ten Cancer Research Consortium Phase 1b/2 trial in patients with non-small cell lung cancer. Imprime PGG has been well-tolerated and has established proof of concept in trials with more than 400 subjects.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Contact: David Walsh Communications Biothera Pharmaceuticals, Inc. 651-256-4606 [email protected]
